Study of AZD1222 for the Prevention of COVID-19 in Japan
A Phase I/II Randomized, Double-blind, Placebo-controlled Multicentre Study in Participants Aged 18 Years or Older to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19
Sponsor: AstraZeneca
This PHASE1/PHASE2 trial investigates COVID-19 and is currently completed. AstraZeneca leads this study, which shows 12 recorded versions since 2020 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2021 — Apr 2024 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Oct 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Apr 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Aug 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Iqvia Pty Ltd
For direct contact, visit the study record on ClinicalTrials.gov .